Outcomes of acute hepatitis B virus (HBV) in HIV infection with and without HBV-active antiretroviral therapy

Oluwaseun Falade-Nwulia, Eric Carl Seaberg, Anna E. Snider, Charles R. Rinaldo, Steven M. Wolinsky, Mallory D. Witt, Chloe L. Thio

Research output: Contribution to journalArticlepeer-review

Abstract

Men with acute hepatitis B virus (HBV) infection in the Multicenter AIDS Cohort Study from 1985 to 2013 had serological testing to determine proportions with HBV recovery or chronic hepatitis B (CHB). A similar proportion of men without human immunodeficiency virus (HIV) and men with HIV receiving HBV-active antiretroviral therapy (ART) developed CHB [8.2%, 95% confidence interval (CI) 3.8-15.0% vs. 7.7%, 95% CI 2.00-36.0%]. In contrast, 17.5% (95% CI 8.7-29.9%) of men living with HIV, not on HBV-active ART developed CHB. HBV-active ART protects against developing CHB.

Original languageEnglish (US)
Pages (from-to)991-993
Number of pages3
JournalAIDS (London, England)
Volume35
Issue number6
DOIs
StatePublished - May 1 2021

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Outcomes of acute hepatitis B virus (HBV) in HIV infection with and without HBV-active antiretroviral therapy'. Together they form a unique fingerprint.

Cite this